HMGA2 Polymorphisms and Hepatoblastoma Susceptibility: A Five-Center Case-Control Study

被引：13

作者：

Li, Li ^{[1
]}

Zhuo, Zhenjian ^{[2
]}

Yang, Zhen ^{[1
,3
]}

Zhu, Jinhong ^{[4
]}

He, Xiaoli ^{[1
]}

Yang, Zhonghua ^{[5
]}

Zhang, Jiao ^{[6
]}

Xin, Yijuan ^{[7
]}

He, Jing ^{[2
]}

Zhang, Tiesong ^{[1
]}

机构：

[1] Kunming Childrens Hosp, Yunnan Inst Pediat Res, Yunnan Key Lab Childrens Major Dis Res, Kunming Key Lab Childrens Infect & Immun, 288 Qianxing Rd, Kunming 650228, Yunnan, Peoples R China

[2] Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Guangdong Prov Key Lab Res Struct Birth Defect Di, Dept Pediat Surg,Guangzhou Inst Pediat, Guangzhou 510623, Guangdong, Peoples R China

[3] Kunming Childrens Hosp, Dept Oncol, Kunming 650228, Yunnan, Peoples R China

[4] Harbin Med Univ, Dept Clin Lab, Biobank, Canc Hosp, Harbin 150040, Heilongjiang, Peoples R China

[5] China Med Univ, Dept Pediat Surg, Shengjing Hosp, Shenyang 110004, Liaoning, Peoples R China

[6] Zhengzhou Univ, Dept Pediat Surg, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China

[7] Air Force Med Univ, Xijing Hosp, Clin Lab Med Ctr PLA, Xian 710032, Shaanxi, Peoples R China

来源：

PHARMACOGENOMICS & PERSONALIZED MEDICINE | 2020年 / 13卷

关键词：

hepatoblastoma; HMGA2; polymorphism; susceptibility; TO-MESENCHYMAL TRANSITION; BIRTH CHARACTERISTICS; NEUROBLASTOMA RISK; GENE POLYMORPHISMS; LIVER-CANCER; LET-7; ASSOCIATION; OVEREXPRESSION; EXPRESSION; HEIGHT;

D O I：

10.2147/PGPM.S241100

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Background: Hepatoblastoma is a rare disease. Its etiology remains obscure. No epidemiological reports have assessed the relationship of High Mobility Group A2 (HMGA2) single nucleotide polymorphisms (SNPs) with hepatoblastoma risk. This case-control study leads as a pioneer to explore whether HMGA2 SNPs (rs6581658 A>G, rs8756 A>C, rs968697 T>C) could impact hepatoblastoma risk. Methods: We acquired samples from 275 hepatoblastoma cases and 1018 controls who visited one of five independent hospitals located in the different regions of China. The genotyping of HMGA2 SNPs was implemented using the PCR-based TaqMan method, and the risk estimates were quantified by odds ratios (ORs) and 95% confidence intervals (CIs). Results: In the main analysis, we identified that rs968697 T>C polymorphism was significantly related to hepatoblastoma risk in the additive model (adjusted OR=0.73, 95% CP0.54-0.98, P=0.035). Notably, participants carrying 2-3 favorable genotypes had reduced hepatoblastoma risk (adjusted OR=0.71, 95% CP0.52-0.96, P=0.028) in contrast to those carrying 0-1 favorable genotypes. Furthermore, stratification analysis revealed a significant correlation between rs968697 TC/CC and hepatoblastoma risk for males and clinical stage I+II. The existence of 2-3 protective genotypes was correlated with decreased hepatoblastoma susceptibility in children >= 17 months old, males, and clinical stage I+II cases, when compared to 0-1 protective genotype. Conclusion: To summarize, these results indicated that the HMGA2 gene SNPs exert a weak influence on hepatoblastoma susceptibility. Further validation of the current conclusion with a larger sample size covering multi-ethnic groups is warranted.

引用

页码：51 / 57

页数：7